This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00154/identifier/chemspider/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00154/identifier/chebi/
n4http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00154/identifier/pharmgkb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00154/identifier/kegg-compound/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00154/identifier/pdb/
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB00154/identifier/pubchem-compound/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00154/identifier/pubchem-substance/
n5http://linked.opendata.cz/ontology/drugbank/
n16http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00154/identifier/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00154
rdf:type
n5:Drug
n5:description
A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. [PubChem]
n5:group
nutraceutical approved
n5:indication
For nutritional supplementation, also for treating dietary shortage or imbalance
owl:sameAs
n4:DB00154 n17:DB00154
dcterms:title
Dihomo-gamma-linolenic acid
adms:identifier
n9:5280581 n10:46508866 n11:C03242 n12:LAX n13:4444199 n14:DB00154 n18:53486 n19:PA164743249
n5:mechanismOfAction
DHLA (or DGLA) is a precursor in the synthesis of prostaglandin E1 (PGE1) as well as the series-3 prostaglandins. It also serves as a precursor in the synthesis of eicosapentaenoic acid (EPA). EPA is a precursor of the series-3 prostaglandins, the series-5 leukotrienes and the series-3 thromboxanes. These eicosanoids have anti-thrombogenic, anti-inflammatory and anti-atherogenic properties. PGE1 inhibits platelet aggregation and has a vasodilation action. DHLA has also been shown to reduce the production/activity of tumor necrosis factor alpha.
n5:synonym
C20:3, n-6,9,12 all-cis Dihomo-γ-linolenic acid all-cis-Eicosa-8,11,14-triensaeure 8c,11c,14c-eicosatrienoic acid all-cis-8,11,14-eicosatrienoic acid (Z,Z,Z)-8,11,14-Eicosatrienoic acid Homo-gamma-linolensaeure gamma-Homolinolenic acid DGLA cis,cis,cis-8,11,14-eicosatrienoic acid all-cis-8,11,14-icosatrienoic acid 20:3, n-6,9,12 all-cis (8Z,11Z,14Z)-Icosatrienoic acid all-cis-eicosa-8,11,14-trienoic acid Homo-gamma-linolenic acid 8c,11c,14c-Eicosatriensaeure (Z,Z,Z)-8,11,14-Icosatrienoate 8,11,14-Eicosatrienoic Acid all-cis-icosa-8,11,14-trienoic acid eicosa-8Z,11Z,14Z-trienoic acid (Z,Z,Z)-8,11,14-Icosatrienoic acid
n5:synthesisReference
Hiroshi Kawashima, "Process for production of dihomo-gamma-linolenic acid and lipid containing same." U.S. Patent US20010021522, issued September 13, 2001.
foaf:page
n16:gam_0120.shtml
n5:IUPAC-Name
n6:271B4CE8-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B4CEE-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B4CED-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4CEA-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4CEB-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4CEC-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B4CE6-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B4CFD-363D-11E5-9242-09173F13E4C5 n6:271B4CE4-363D-11E5-9242-09173F13E4C5 n6:271B4CE7-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B4CE5-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B4CF4-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B4CF5-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B4CEF-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B4CF0-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B4CF2-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B4CF1-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B4CF3-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
1783-84-2
n5:category
n5:Bioavailability
n6:271B4CF9-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B4CFB-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B4CFC-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B4CF8-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B4CF7-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B4CFA-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B4CE9-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B4CF6-363D-11E5-9242-09173F13E4C5